TABLE 2.
Summary of characteristics and results of clinical trials of antimicrobial agents used for eradication of methicillin-resistant Staphylococcus aureus (MRSA) colonization
| Reference (year) | n | Interventions | Length of follow-up (days) | Results |
|---|---|---|---|---|
| 53 (1990) | 21 | Ciprofloxacin + rifampin x14 days vs TMP-SMX + rifampin x14 days | 180 | 30% eradication with ciprofloxacin vs 40% with TMP-SMX (RR 0.6; 95% CI 0.2 to 1.9) |
| 106 (1993) | 80 | Novobiocin + rifampin x7 days vs TMP-SMX + rifampin x7 days | 14 | 67% eradication with novobiocin vs 53% with TMP-SMX (RR 1.3; 95% CI 0.9 to 1.6) |
| 107 (1994) | 35 | Rifampin x5 days vs minocycline x 5 days vs rifampin + minocycline x5 days vs no treatment | 90 | 70% eradication with rifampin vs 14% with no treatment (RR 4.9, 95% CI 0.8 to 31.5); 38% eradication with minocycline vs 14% with no treatment (RR 2.6; 95% CI 0.35 to 19.9) 50% eradication with rifampin + minocycline vs 14% with no treatment (RR 3.5; 95% CI 0.5 to 23.8) |
| 108 (1995) | 72 | Mupirocin ointment x5 days vs fusidic acid ointment + TMP-SMX x5 days | 90 | 74% eradication with mupirocin vs 71% fusidic acid + TMP-SMX (RR 1.1; 95% CI 0.6 to 1.9) |
| 105 (1999) | 102 | Mupirocin ointment vs placebo x5 days | 26 | 25% eradication with mupirocin vs 18% with placebo(RR 1.4; 95% CI 0.6 to 3.0) |
| 109 (2000) | 16 | Fusidic acid orally x7 days vs no treatment | 14 to 77 | 33% eradication with fusidic acid vs 50% with no treatment (RR 0.7; 95% CI 0.2 to 2.4) |
TMP/SMX Trimethoprim-sulphamethoxazole; Vs Versus